Skyepharma’s pre-close trading update highlights the continued encouraging growth in demand for flutiform® and the group’s confidence in the full year outlook. We note with interest that Mundipharma has completed recruitment into its clinical trial of flutiform® in COPD and we expect data by end of 2016. Overall trading remains in line with the Board’s expectations and we believe the group’s highly attractive offering puts it in a strong position to drive significant shareholder returns over the ....
25 Jun 2015
Trading update highlights continued flutiform® progress
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Trading update highlights continued flutiform® progress
SkyePharma (SKP:LON) | 0 0 0.0% | Mkt Cap: 470.3m
- Published:
25 Jun 2015 -
Author:
Sheena Berry -
Pages:
3
Skyepharma’s pre-close trading update highlights the continued encouraging growth in demand for flutiform® and the group’s confidence in the full year outlook. We note with interest that Mundipharma has completed recruitment into its clinical trial of flutiform® in COPD and we expect data by end of 2016. Overall trading remains in line with the Board’s expectations and we believe the group’s highly attractive offering puts it in a strong position to drive significant shareholder returns over the ....